Detailed price information for Arrivent Biopharma Inc (AVBP-Q) from The Globe and Mail including charting and trades.
US-listed ArriVent lost nearly half its value after a Chinese-licensed cancer drug failed a late-stage trial.
ArriVent BioPharma announced its Phase 3 lung cancer trial for firmonertinib missed the primary endpoint but showed secondary benefits.
ArriVent BioPharma (AVBP) stock plunges 50% as lead asset fails in a late-stage trial for a type of lung cancer. Read more here.
ArriVent BioPharma Inc. (NASDAQ:AVBP) stock fell on Tuesday with a session volume of 14.10 million compared to the average volume of 524.163 thousand, according to Benzinga Pro data. The company announced that its Phase 3 FURVENT trial evaluating firmonertinib failed to achieve its primary endpoint. The clinical-stage biopharmaceutical company tested the drug as a standalone therapy for patients suffering from previously untreated, locally advanced, or metastatic non-squamous non-small cell lung
This is the newest page. Registered accounts read further back.